An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients.

• Phase: Phase 3

Details

• Lead Sponsor: Kissei Pharmaceutical Co., Ltd.
• Treatments: Thyrotropin-Releasing Hormone

Criteria

Inclusion Criteria:

• Japanese SCD patients with mild to moderate ataxia (Completion of the KPS1301 study)

Exclusion Criteria:

• Less than 75% of compliance in KPS1301 study